본문으로 가기

학회지 검색

  • Journal of Multiple Sclerosis 7(2):49-54, 2016
  • Alemtuzumab in the Treatment of Multiple Sclerosis
  • Jeeyoung Oh
  • Department of Neurology, Konkuk University Medical Center, Seoul, Korea
Alemtuzumab is a humanized monoclonal antibody against CD52 and is recently approved for the second-line therapy of active relapse-remitting multiple sclerosis in Korea. Alemtuzumab leads to a rapid and long-lasting depletion of peripheral T and B cells with repopulation of immune cell composition resulting in the rebalancing of immune-tolerance network. However, it has a considerable adverse effects including infusion associated reaction, infection, and secondary autoimmune disease requiring close and regular monitoring during and for 4 years after the final infusion cycle. This review will provide a summary of mechanism of action, data from the pivotal clinical studies, and safety profiles of alemtuzumab. Journal of Multiple Sclerosis 7(2):49-54, 2016
  • keyword : Alemtuzumab, CD52, Monoclonal antibody, Multiple sclerosis